As an important downstream target gene of β-catenin, targeted inactivation of c-myc impairs tumorigenesis induced by APC defect in the mouse CRC model29, indicating that c-myc is a promising drug target for colorectal cancer. This evidence concerns the gene APC and colorectal carcinoma.